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Peripheral neuropathic pain is a disabling condition resulting from nerve injury. It is characterized by the 
dysregulation of voltage-gated sodium channels (Navs) expressed in dorsal root ganglion (DRG) sensory neu-
rons. The mechanisms underlying the altered expression of Navs remain unknown. This study investigated the 
role of the E3 ubiquitin ligase NEDD4-2, which is known to ubiquitylate Navs, in the pathogenesis of neuro-
pathic pain in mice. The spared nerve injury (SNI) model of traumatic nerve injury–induced neuropathic pain 
was used, and an Nav1.7-specific inhibitor, ProTxII, allowed the isolation of Nav1.7-mediated currents. SNI 
decreased NEDD4-2 expression in DRG cells and increased the amplitude of Nav1.7 and Nav1.8 currents. The 
redistribution of Nav1.7 channels toward peripheral axons was also observed. Similar changes were observed 
in the nociceptive DRG neurons of Nedd4L knockout mice (SNS-Nedd4L–/–). SNS-Nedd4L–/– mice exhibited ther-
mal hypersensitivity and an enhanced second pain phase after formalin injection. Restoration of NEDD4-2 
expression in DRG neurons using recombinant adenoassociated virus (rAAV2/6) not only reduced Nav1.7 and 
Nav1.8 current amplitudes, but also alleviated SNI-induced mechanical allodynia. These findings demonstrate 
that NEDD4-2 is a potent posttranslational regulator of Navs and that downregulation of NEDD4-2 leads to 
the hyperexcitability of DRG neurons and contributes to the genesis of pathological pain.
Introduction
Neuropathic pain is a direct consequence of alterations in the 
somatosensory system. It affects approximately 7% of the general 
population and is insufficiently treated with currently available 
drugs (1). Following nerve injury, there is ectopic spontaneous 
activity of afferent neurons due to the increased expression of 
voltage-gated sodium channels (Navs) (2, 3). This hyperexcitabil-
ity mediates enduring changes in the nervous system, contrib-
uting to both peripheral and central sensitization (4). Navs are 
heteromeric glycosylated protein complexes composed of a large 
pore-forming α subunit and auxiliary β subunits (5, 6). Nine 
genes encode for distinct channel isoforms (Nav1.1 to Nav1.9), 
each displaying specific properties. They are classified according 
to their sensitivity to tetrodotoxin (TTX). All isoforms, except 
Nav1.4 and Nav1.5, are expressed in the dorsal root ganglia 
(DRG) and trigeminal ganglia (TG) nociceptive neurons, with 
Nav1.8 and Nav1.9 being expressed almost exclusively in DRG/
TG neurons and Nav1.7 in DRG/TG and sympathetic ganglion 
neurons (7). Nav1.7 is expressed at higher levels in DRG/TG than 
are other TTX-sensitive isoforms (7, 8) and plays an essential 
role in the modulation of human pain perception. Naturally 
occurring mutations in SCN9A, the gene encoding Nav1.7, lead 
to either congenital insensitivity or severe episodic hypersen-
sitivity to pain (9–11). In addition, Nav1.7 and Nav1.8 gain-of-
function mutations in painful peripheral neuropathy syndromes 
were recently described (12, 13). Not only are Nav1.7 and Nav1.8 
important in inherited pain disorders, but also in acquired pain 
disorders, where their increased expression has already been 
linked to diverse chronic pain symptoms (14–16). Studies using 
knockout mice have implicated Nav1.7 and Nav1.8 in acute and 
inflammatory pain (17–20), but their involvement in hyperexcit-
ability and neuropathic pain remains to be determined.
The control of Nav density at the cell membrane is crucial to ensur-
ing normal neuronal excitability. Despite extensive research on the 
subject, the regulation of Navs in neuropathic pain remains poorly 
understood. Navs are subject to posttranslational modifications 
that may influence their cell membrane availability. Ubiquitylation 
is a key process that orchestrates the internalization and subsequent 
degradation or recycling of Navs (21). The final and limiting step 
is the covalent attachment of ubiquitin moieties to lysine residues 
of the target protein. This is accomplished by ubiquitin protein 
ligases, such as NEDD4-2 (neuronal precursor cell expressed devel-
opmentally downregulated-4 type 2). NEDD4-2 is a member of the 
NEDD4/NEDD4-like E3 subfamily of ubiquitin ligases, whose type 
I WW domains interact with the PY motifs (PPxY) of target proteins. 
All Nav isoforms, except Nav1.4 and Nav1.9, possess a PY motif and 
are potential targets of NEDD4-2. In vitro experiments have indi-
cated that NEDD4-2 can negatively regulate the epithelial sodium 
channel ENaC (22) and Navs (23, 24). The functional relevance of 
NEDD4-2 in sensory neurons, as well as its possible involvement in 
pain sensitivity, have yet to be investigated.
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NEDD4-2 was recently shown to be decreased in rat DRG in 
the spared nerve injury (SNI) model of traumatic nerve injury–
induced neuropathic pain (25). The present study postulated that 
reduced levels of NEDD4-2 jeopardize the correct addressing or 
anchoring of Navs in DRG nociceptive neurons. NEDD4-2 expres-
sion was controlled in cellular expression systems and in mice with 
DRG-specific gene deletions or rAAV-mediated gene transfers. 
This enabled the selective investigation of the effect of NEDD4-2 
on Nav1.7 and Nav1.8 currents, as well its impacts on pain sensi-
tivity. The results provide what we believe to be the first in vivo 
mechanistic evidence that NEDD4-2 enables the fine-tuning of 
neuronal excitability in DRG cells. Furthermore, these results may 
demonstrate that the pathological reduction of NEDD4-2 under-
lies traumatic nerve injury–induced neuropathic pain.
Results
Peripheral nerve injury reduces NEDD4-2 expression in DRG. The pro-
tein and mRNA levels of Nedd4L were measured to explore whether 
Nedd4L is regulated after nerve injury in mice and whether it contrib-
utes to phenotypic changes in DRG neurons. A substantial decrease 
of NEDD4-2 expression was observed by immunofluorescence 
in lumbar L4/L5 DRG 7 days after SNI (Figure 1, A and B). This 
decrease was further quantified using Western blot analysis. SNI 
decreased NEDD4-2 protein levels by greater tha 60% in DRG, an 
effect that lasted for at least 6 weeks (Figure 1C). Both SNI and spinal 
nerve ligation (SNL) reduced Nedd4L transcript levels (Figure 1D). 
Nedd4L mRNA was abundantly expressed in lumbar L4/5 DRG and 
was the only member of the Nedd4/Nedd4-like E3 subfamily to be 
downregulated after SNI (Figure 1E).
NEDD4-2 interacts with, ubiquitylates, and downregulates Nav1.7 in 
HEK293 cells. Since Nav1.7 is essential for pain sensation, NEDD4-
2 downregulation of Nav1.7 in mammalian cells was investigated, 
as previously reported in Xenopus oocytes (24). Whole-cell Na+ 
currents (INa) were recorded in HEK293 cells cotransfected with 
Nav1.7 and NEDD4-2. NEDD4-2 decreased Nav1.7 current den-
sity by approximately 80% (Figure 2, A and B). The biophysical 
properties of Nav1.7 were unaffected by NEDD4-2 (Supplemen-
tal Table 1 and Supplemental Figure 1A; supplemental material 
Figure 1
Peripheral nerve injury reduces NEDD4-2 expression in DRG. (A 
and B) Immunofluorescence of NEDD4-2 in coronal sections of 
L4 DRG from sham-operated and SNI mice. Scale bars: 30 μm. 
(C) Representative Western blot analysis showing the decrease 
in NEDD4-2 at days 7, 21, and 42 after SNI in L4/5 DRG and its 
associated quantification. Data are expressed as the means ± SEM; 
n = 4 samples for each time point per group. ***P < 0.001 by 1-way 
ANOVA with Bonferroni’s post-hoc test. GAPDH was used as a 
loading control. Lanes were run on the same gel but were noncon-
tiguous. (D) Effect of SNI and SNL on Nedd4-1 and Nedd4L tran-
scripts in L4/5 DRG 7 days after SNI or SNL (injury of L5 spinal 
nerve). Bar graph showing transcriptional levels of Nedd4-1 and 
Nedd4L normalized to GAPDH in SNI and SNL groups over the 
control group (sham for SNI and L4 DRG for SNL). Data represent 
the mean ± SEM; n = 4 samples per group. Isolated L4/5, L5, or L4 
DRG from 2 mice were pooled for each sample and run in triplicate. 
*P = 0.011, **P = 0.004, Student’s t test. (E) Constitutive transcript 
levels of Nedd4/Nedd4-like E3 subfamily members in L4/5 DRG 7 
days after sham and SNI surgery. Transcript levels were normal-
ized using HPRT as a reference gene and further normalized to 
Nedd4L levels in sham-operated mice. Data are expressed as the 
means ± SEM; n = 3–4 samples per group, which were run in trip-
licate. **P = 0.005, Student’s t test. We detected no amplification of 
NedL1 in the DRG samples.
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available online with this article; doi:10.1172/JCI68996DS1), sug-
gesting that NEDD4-2 mainly reduces the number of channels 
at the cell surface. Cell-surface proteins were then biotinylated 
and precipitated. Upon NEDD4-2 cotransfection, expression of 
the fully glycosylated form of Nav1.7 (Supplemental Figure 1B) 
was decreased by approximately 50% in the plasma membrane 
fraction, but remained unchanged in the total lysate (Figure 2C, 
see also Supplemental Figure 1, C and D, for additional in vitro 
experiments). The interaction between Nav1.7 and NEDD4-2 was 
examined by pull-down experiments using GST fused to the fur-
thest 66 C-terminal amino acid residues of Nav1.7, which include 
the PY motif (GST-Cter-Nav1.7). Nav1.7 GST fusion proteins 
interacted with endogenous and transfected NEDD4-2, whereas 
GST alone did not (Figure 2D). Finally, whether Nav1.7 could 
be a substrate of NEDD4-2 ubiquitylating activity was tested 
by pulling down ubiquitylated proteins using GST fused to the 
ubiquitin-binding proteasomal subunit S5A (GST-S5A). Overex-
pression of NEDD4-2 substantially increased GST-S5A–bound 
Nav1.7 (Figure 2E). Taken together, these results support a model 
in which NEDD4-2 interacts with and ubiquitylates Nav1.7 and 
thus controls the level of the functional channel at the cellular 
membrane in mammalian cells. Additional in vitro experiments 
demonstrating the importance of the PY motif in the NEDD4-2 
downregulatory effect on Nav1.7 are presented in Supplemental 
Figure 2, A–F and in the Supplemental Results.
SNI changes the expression of Navs. In freshly dissociated L4/5 
mouse DRG neurons, the different Nav components were func-
tionally dissected out 1 week after SNI by performing whole-cell 
patch-clamp recordings. From total INa (Navtotal), the specific 
Nav1.7 channel blocker ProTxII (26) and TTX were used to isolate 
the following 3 currents: the Nav1.7-mediated current (ProTxII-
sensitive current, referred to as Nav1.7 for simplicity), the remain-
Figure 2
NEDD4-2 downregulates membrane Nav1.7. (A) Representative cur-
rent traces obtained with a V-I protocol (see Methods) on HEK293 
cells after Nav1.7 transfection or cotransfection with NEDD4-2. (B) 
Quantification of current densities from A. NEDD4-2 reduced Nav1.7 
current density (***P < 0.001). See Supplemental Figure 1A and 
Supplemental Table 1 for values and biophysical properties. (C) 
Surface biotinylation of HEK293 cells and their associated quantifi-
cation. In membrane fractions, NEDD4-2 reduced the fully glycosy-
lated form of Nav1.7 (***P < 0.001), whereas the core glycosylated 
form remained unchanged (P = 0.416). Nav1.7 total expression was 
unchanged (P = 0.337; Input). The β1 subunit of the NaK/ATPase 
and actin were used as loading controls in input and biotinylation 
fractions, respectively. Deglycosylation experiments are presented 
in Supplemental Figure 1B. NEDD4-2 antibody recognizes both 
endogenous (120 kDa) and transfected (100 kDa) proteins. (D) 
GST pull-down experiment showing Nav1.7 PY motif interaction with 
NEDD4-2. HEK293 cells were transfected with NEDD4-2, and sol-
uble fractions were mixed GST proteins or GST-Cter-Nav1.7 fusion 
proteins. Bound NEDD4-2 was analyzed by Western blot. The entire 
Western blot with PY motif mutants can be seen in Supplemental 
Figure 2E. (E) NEDD4-2–mediated ubiquitylation. HEK293 cells 
were transfected with Nav1.7 or cotransfected with NEDD4-2, and 
soluble fractions were mixed with GST-S5A proteins to pull down 
ubiquitylated proteins. Bound Nav1.7 was analyzed by Western blot-
ting. The entire Western blot with PY motif mutants can be seen in 
Supplemental Figure 2F.
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ing TTX-sensitive currents (Nav1.1, Nav1.2, Nav1.3, and Nav1.6 
currents collectively referred to as NavrTTXs), and the TTX-resis-
tant currents (referred to as Nav1.8, since Nav1.9 was inactivated 
by an ad-hoc electrophysiological protocol; see Methods) (Figure 
3A). Recorded cells were small neurons (<30 pF), considered to 
be nociceptive neurons (27). Despite the fact that the distinction 
between intact or severed neurons was not made, a significant 
increase in the Navtotal (P = 0.013) and NavrTTXs (P = 0.021) 
current densities after SNI were measured (ipsilateral compared 
with the contralateral side, Supplemental Figure 3A). Since the 
expression of Navs in DRG is heterogeneous, the analysis was 
refined by segregating cells into fast and slow neurons, as previ-
ously reported (27). A neuron was characterized as slow when the 
INa density ratio of the Nav1.8/Navtotal was greater than 0.5, with 
Nav1.8 displaying slower inactivation kinetics. Conversely, when 
this ratio was less than 0.5, the neuron was defined as fast (27). 
This selection revealed that SNI significantly increased Nav1.7 
and Nav1.8 current densities in the slow subpopulation only (Fig-
ure 3B). The fast subpopulation showed a small but significant 
increase in NavrTTXs alone (Figure 3C; P = 0.014).
SNI had only a minor impact on the biophysical properties 
(voltage dependence of steady-state activation and inactivation) 
of some of the Nav components (Supplemental Table 2). In line 
with previous studies (28, 29), nerve injury induced an acceleration 
of the recovery from inactivation (repriming) for every component 
of INa of the fast subpopulation (Supplemental Table 2).
Western blots of pooled L4/5 DRG revealed no detectable modi-
fication of the expression levels of Navtotal, nor that of Nav1.7 (P = 
0.039) or Nav1.8 (P = 0.024) 1 week after SNI (Figure 3D). However, 
Nav1.7 and Navtotal levels were significantly increased in the sciatic 
nerve. Nav1.8 was undetectable in the nerves of sham-operated ani-
mals. The signal intensity was not significantly modified after SNI, 
but a distinct band at the expected molecular weight (230–240 kDa) 
was visible in all 4 SNI samples (see Supplemental Figure 3B).
Figure 3
Increase in Nav1.7 and Nav1.8 currents in DRG neurons and increased expression of Nav1.7 along the sciatic nerve after SNI. (A) Typical 
recordings of INa in DRG neurons using the V-I protocol and pharmacological isolation of Navtotal, Nav1.7, Nav1.8, and NavrTTXs currents 
with ProTxII and TTX (see Methods). (B and C) Scatter dot plot representing Navtotal, Nav1.7, Nav1.8, and NavrTTXs current densities in 
contralateral and ipsilateral sides recorded in L4/5 DRG neurons 1 week after SNI. Slow (B, in cyan) and fast (C, in magenta) neurons are 
shown. Mann-Whitney U test. See Supplemental Figure 3A for the total population and see Supplemental Table 2 for values and biophysical 
properties. (D) Left panel: representative Western blot analysis and quantification of Nav α subunits: Navtotal, Nav1.7, and Nav1.8 in DRG 7 
days after SNI. No modifications in Navtotal (P = 0.496), Nav1.7 (P = 0.690), or Nav1.8 (P = 0.311) were observed in sham- and SNI-oper-
ated mice. Right panel: same as above, but for sciatic nerve preparation. Nav1.7 (*P = 0.045) and Navtotal (*P = 0.021) were significantly 
increased in SNI compared with the sham samples. The Nav1.8 signal in the SNI sample did not reach significance compared with the 
background signal in the sham-operated group (P = 0.105) (see Supplemental Figure 3B). The 2 open arrowheads correspond to a distinct 
band of Nav1.8, with lower molecular weight than the band observed at 250 kDa. Data are expressed as the means ± SEM; n = 4 samples 
for each group. Student’s t test. Tubulin was used as a loading control. Int., intensity.
Downloaded on July 23, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/68996
research article
3006 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 7   July 2013
Figure 4
SNS-Nedd4L–/– mice show increased Nav1.7 and Nav1.8 currents in DRG neurons and 
increased expression of Nav1.7 along the sciatic nerve. (A and B) Immunofluorescence 
of NEDD4-2 in coronal sections of L4 DRG from Nedd4Lfl/fl and SNS-Nedd4L–/– mice. 
Scale bars: 30 μm. (C and D) Immunofluorescence and corresponding bright-field 
images of NEDD4-2 in DRG neurons from Nedd4Lfl/fl and SNS-Nedd4L–/– mice after 
whole-cell patch-clamp recordings (36 hours after dissociation). Scale bars: 30 μm. (E) 
Western blot and quantification showing NEDD4-2 decrease in the DRG (**P = 0.003) 
of SNS-Nedd4L–/– mice compared with control Nedd4Lfl/fl mice. (F and G) Scatter dot 
plots representing Navtotal, Nav1.7, Nav1.8, and NavrTTXs current densities in L4/5 DRG 
neurons from SNS-Nedd4L–/– and Nedd4Lfl/fl mice. Slow (F, in cyan) and fast (G, in 
magenta) neurons are shown. Mann-Whitney U test. See Supplemental Figure 4A for 
total population and Supplemental Table 3 for values and biophysical properties. (H) 
Left panel: Western blot analysis and quantification of Nav α subunits in the DRG of 
SNS-Nedd4L–/– and Nedd4Lfl/fl mice. No significant modifications in Navtotal (P = 0.054) 
or Nav1.7 (P = 0.646) were observed, whereas the Nav1.8 signal was increased in the 
SNS-Nedd4L–/– mice (*P = 0.020). Right panel: same as above, but for sciatic nerves. 
Nav1.7 was significantly increased (*P = 0.022), whereas the increase in Navtotal was 
not significant (P = 0.089). Data are expressed as the means ± SEM; n = 4 samples for 
each group. Student’s t test. Tubulin was used as a loading control in E and H.
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Nav expression in SNS-Nedd4L–/– knockout mice. To investigate 
the contribution of NEDD4-2 to the expression of Navs in DRG 
in vivo and its impact on pain, a DRG neuron–specific Nedd4L- 
deficient mouse line was generated (SNS-Nedd4L–/–; see Supple-
mental Methods). Mice carrying a homozygous Nedd4L flox allele 
(Nedd4Lfl/fl) (30) were crossed with mice heterozygously express-
ing Cre recombinase under the control of the Nav1.8 promoter 
(referred to as SNS-Cre), which is predominantly active in DRG 
nociceptive neurons (31). Cre expression in this mouse line has 
been extensively characterized (32) and differs from another Nav1.8-
Cre mouse line generated by the Wood laboratory (33). NEDD4-2 
expression was greatly reduced in the DRG neurons of SNS-
Nedd4L–/– mice (Figure 4, A–E). A slight signal was still detectable 
in the SNS-Nedd4L–/– mice, most likely due to a residual expression 
of NEDD4-2 in neurons not expressing Nav1.8 (Figure 4E). Whole-
cell patch-clamp recordings showed a 2-fold upregulation of Nav-
total, Nav1.7 (P = 0.027), and Nav1.8 (P < 0.001) current densities 
in neurons from SNS-Nedd4L–/– mice (Supplemental Figure 4A and 
Supplemental Table 3) compared with neurons from Nedd4Lfl/fl 
control littermates. The NavrTTXs component was not signifi-
cantly altered. Subsequent analyses of slow and fast neuronal 
subpopulations revealed that, similar to the SNI condition, the 
changes were predominant in slow neurons (a 2-fold increase for 
Navtotal [P = 0.001], Nav1.7 [P = 0.042], and Nav1.8 [P < 0.001] 
current densities) (Figure 4, F and G). The biophysical properties 
were largely unaltered in the knockout mice (Supplemental Table 
3), consistent with a major role of NEDD4-2 in the regulation of 
Nav1.7 and Nav1.8 membrane density.
We then evaluated whether the expression of Navs was modified 
in DRG and the sciatic nerves of SNS-Nedd4L–/– mice (Figure 4H). 
We observed a markedly increased Western blot signal for Nav1.8 
in the DRG of knockout mice, while the signal was undetectable 
in Nedd4Lfl/fl DRG neurons. These observations were confirmed by 
immunofluorescence measurements (Supplemental Figure 4B). 
Although the Nav1.7 signal from DRG was not changed between 
the groups, a stronger signal was observed in the sciatic nerves of 
the SNS-Nedd4L–/– mice, similar to that observed after SNI. Nav1.8 
immunoreactivity was not detected in the sciatic nerves of the 
knockout mice or in those of the control mice, suggesting that the 
mechanisms underlying Nav1.8 redistribution in nerves after SNI 
are independent of NEDD4-2 downregulation.
Pain-related responses in SNS-Nedd4L–/– knockout mice. We then 
investigated whether peripheral deficiency of NEDD4-2 could 
modify pain behavior. While response latencies to radiant heat 
(tail-flick test) (Figure 5B) and acute mechanical nociception (tail 
pressure test) (Figure 5C) were unchanged, acute thermal hyper-
sensitivity in SNS-Nedd4L–/– mice was observed with the hot-plate 
test at 52°C and 55°C (Figure 5A). We also performed the hot-
Figure 5
SNS-Nedd4L–/– mice show increased thermal sensitivity and an increased second pain phase after formalin injection. (A) Significantly higher 
thermal sensitivity was detected in the hot-plate test at 52°C and 54°C in SNS-Nedd4L–/– mice. P = 0.112 at 49°C, **P = 0.009 at 52°C, and 
**P = 0.008 at 55°C; Mann-Whitney U test. (B) No differences were observed in the tail-flick test. P = 0.414 at intensity 4 and P = 0.830 at intensity 
7 (AU); Mann-Whitney U test. (C) Responses to the tail pressure test were unchanged. P = 0.452, Student’s t test. (D) Basal responses to mechan-
ical stimulation and development of SNI-related mechanical allodynia-like behavior were not different. P > 0.05, 2-way ANOVA on log values with 
post-hoc Bonferroni’s tests. (E) Higher thermal sensitivity was detected at 52°C in SNS-Nedd4L–/– mice, but this effect was not further increased 
after SNI. *P < 0.05 between groups using 2-way ANOVA with repeated measures. *P < 0.05 on day 7 with post-hoc Bonferroni’s tests. (F) Plan-
tar test 35 days after SNI. Higher thermal sensitivity was detected in SNS-Nedd4L–/– mice as compared with the noninjured paws of Nedd4Lfl/fl 
mice (contralateral). SNI induced thermal hyperalgesia in the injured paws of Nedd4Lfl/fl mice compared with noninjured paws. *P = 0.013 and 
**P = 0.006 at intensity 3 (AU), Student’s t test. (G) Time course of the nocifensive response to formalin injection revealed an increased response 
in SNS-Nedd4L–/– mice during the second phase of the test. ***P < 0.001, 2-way ANOVA with repeated measures with post-hoc Bonferroni’s tests. 
Insert shows the bar graph of this effect through AUC quantification. **P = 0.009, Mann-Whitney U test. Data are expressed as the means ± SEM 
and n = 7– 28 animals per group for all panels.
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plate test at 52°C after SNI (Figure 5E). Nedd4Lfl/fl mice did not 
develop SNI-induced hyperalgesia. The observed thermal hyper-
sensitivity in the SNS-Nedd4L–/– mice under basal conditions was 
not further enhanced after SNI. The response of the hot-plate test 
depends on the strength applied by the paw to the plate, which may 
be impeded after SNI surgery due to the transection of motor neu-
rons. To overcome this problem, we performed the plantar test, an 
alternative thermal sensitivity test independent of strength, at the 
end of the SNI time course (i.e., 35 days after SNI). As illustrated 
in Figure 5F, the noninjured paws of SNS-Nedd4L–/– mice demon-
strated more thermal hypersensitivity than the noninjured paws 
of Nedd4Lfl/fl mice. SNI induced thermal hypersensitivity in the 
injured paws of Nedd4Lfl/fl mice, but did not further enhance the 
hypersensitivity in the injured paws of SNS-Nedd4L–/– mice. Basal 
mechanical innocuous sensitivity was not altered in Nedd4Lfl/fl 
mice (see baseline [BL] in the von Frey filaments test in Figure 5D). 
After SNI, the decrease in the withdrawal threshold related to the 
development of mechanical allodynia–like behavior was indis-
tinguishable between groups. Intraplantar injection of formalin 
in SNS-Nedd4L–/– mice led to an increased and earlier maximal 
Figure 6
Delivery of rAAV2/6-NEDD4-2 viral vector decreases functional currents after SNI and alleviates mechanical allodynia. (A–D) Immunofluorescence 
of NEDD4-2 in coronal sections of L4 ipsilateral DRG injected with rAAV2/6-NEDD4-2 or saline solution in sham- and SNI-operated mice. Scale bars: 
30 μm. (E and F) Scatter dot plots representing Navtotal, Nav1.7, Nav1.8, and NavrTTXs current densities 1 week after SNI in noninfected DRG neurons 
(NINF), rAAV2/6-NEDD4-2–infected cells (INFNEDD4–2), and in the control group infected with the rAAV2/6-NEDD4-2CS vector (INFNEDD4-2CS). Slow (E, 
in cyan) and fast (F, in magenta) neurons are shown. Nonparametric 1-way ANOVA (Kruskal-Wallis test) with Dunn’s post-hoc test. See Supplemental 
Figure 5F for total population, Supplemental Table 5 for biophysical properties and values, and Supplemental Figure 5, A–E. (G) Basal thermal sensi-
tivity showed no difference at 49°C (P = 0.987), 52°C (P = 0.186), or 55°C (P = 0.673) in the hot-plate test between the 2 groups. Student’s t test. (H) 
An increase in tail-flick latency (P = 0.018 at intensity 7) for high-intensity stimulation in the rAAV2/6-NEDD4-2 group was observed. Mann-Whitney 
U test. (I) Tail pressure sensitivity was increased in mice infected with rAAV2/6-NEDD4-2. **P = 0.006, Student’s t test. (J) Basal responses to innoc-
uous mechanical stimulation were not different between the 2 strands, but the development of mechanical allodynia was significantly diminished in 
rAAV2/6-NEDD4-2–infected mice. ***P < 0.001 at day 7 and **P < 0.01 at day 14; 2-way ANOVA on log values with post-hoc Bonferroni’s tests. Data 
are expressed as the mean ± SEM; n = 12–15 for rAAV2/6-stuffer and rAAV2/6-NEDD4-2.
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response (peak at 30.4 ± 1.4 minutes in SNS-Nedd4L–/– mice com-
pared with 36.3 ± 1.3 minutes in Nedd4Lfl/fl mice; P = 0.039) during 
the early second phase as compared with the Nedd4Lfl/fl mice, sug-
gesting a central consequence of increased peripheral activity due 
to Nedd4L deletion (Figure 5G). Acute nociception during phase 1 
of the formalin test was similar between the groups.
Functional effects of in vivo exogenous NEDD4-2 overexpression. To test 
whether the rescue of NEDD4-2 reduction in DRG may function-
ally modify Nav expression and influence the course of SNI-induced 
hypersensitivity, we generated a recombinant serotype 6 adenoas-
sociated viral vector expressing NEDD4-2 (rAAV2/6-NEDD4-2, 
Supplemental Figure 5A). Two control vectors were designed: 
noncoding (stuffer) vectors and those expressing the catalytically 
inactive form of NEDD4-2 (NEDD4-2CS). The infection efficiency 
of the viral vector was recently demonstrated for small DRG neu-
rons (presumably nociceptors) after intrathecal delivery, and the 
transduction efficiency was shown to be entirely preserved after 
peripheral nerve injury (34). Immunofluorescence experiments 
showed that rAAV2/6-NEDD4-2 increased NEDD4-2 expression 
in L4/5 DRG under naive conditions and after SNI (Figure 6, A–D 
and Supplemental Figure 5B). INa measurements were taken of small 
DRG neurons after Nedd4L gene delivery, followed by single-cell PCR 
to identify infected (INF) and noninfected neurons (NINF). In naive 
animals, NEDD4-2 overexpression altered neither the INa density, 
nor the biophysical properties of rAAV2/6-NEDD4-2–infected DRG 
neurons when compared with cells infected with the control vector 
(INFNEDD4–2CS) or the NINF neurons (Supplemental Figure 5, C–E, 
and Supplemental Table 4). In the SNI condition, exogenous expres-
sion of NEDD4-2 substantially reduced the INa densities for Navtotal 
(by 49%), Nav1.7 (by 53%), and Nav1.8 (by 58%) of infected neurons 
(INFNEDD4–2). This was observed mainly in the fast subpopulation 
of DRG neurons as compared with the controls (INFNEDD4–2CS and 
NINF; Figure 6F and Supplemental Table 5), accounting for the ten-
dency observed in the total population (Supplemental Figure 5F). 
The virus can potentially transduce all types of DRG cells, which 
may explain why effects were observed only in the fast population 
and not in the slow population. Before determining whether restor-
ing NEDD4-2 expression with this viral vector would impact SNI-
mediated hypersensitivity, we first tested the basal sensitivity. The 
response to innocuous mechanical stimuli remained unchanged 
(see baseline in the von Frey filaments test; Figure 6J). Responses 
to the hot-plate test (Figure 6G) and the low intensity of the tail-
flick tests were not different between rAAV2/6-NEDD4-2 or control 
vector (rAAV2/6-stuffer) mice (Figure 6H). However, mice infected 
with rAAV2/6-NEDD4-2 showed mild, but significant, hyposen-
sitivities to the higher stimulus of the tail-flick test, whereas they 
showed mild, but significant, hypersensitivity to mechanical noci-
ception (tail pressure test; Figure 6I). The development of mechan-
ical allodynia following SNI was repressed in rAAV2/6-NEDD4-2–
infected mice as compared with mice infected with the noncoding 
vector (Figure 6J), highlighting the behavioral consequences of the 
decrease in INa current.
Discussion
The present study provides what we believe to be the first in vivo 
evidence that the ubiquitin ligase NEDD4-2 exerts a strong influ-
ence on the neuronal excitability of the sensory system, and that 
dysregulation of this regulatory mechanism contributes to pain 
hypersensitivity. This is mainly due to a pathological redistribu-
tion of Nav1.7 and Nav1.8 in DRG cells.
Peripheral neuropathic pain develops across different disease 
states as a result of different mechanisms and depends on mul-
tiple etiological factors. In this study, we used the SNI model, a 
common traumatic nerve injury–induced neuropathic pain ani-
mal model (35). Although this may not mimic the mechanisms of 
other neuropathic pain syndromes, its fast onset and prolonged 
maintenance of thermal and mechanical hypersensitivity renders 
it very valuable.
Using this model of neuropathic pain in mice, NEDD4-2 expres-
sion was found to be substantially decreased in DRG neurons, 
with a concomitant increase in Nav1.7 and Nav1.8 current densi-
ties. The results also demonstrated that knocking out NEDD4-2 
expression in nociceptive neurons increased Nav1.7 and Nav1.8 
levels and enhanced basal pain sensitivity. Conversely, the overex-
pression of NEDD4-2 using rAAV2/6 vectors led to a reduction in 
Nav1.7 and Nav1.8 current densities and a decrease in neuropathic 
pain–like allodynia in the SNI model.
The different components of INa were identified in mouse 
DRG neurons by the use of specific electrophysiological proto-
cols and toxins. Nav1.7-mediated currents were isolated with the 
perfusion of ProTxII (26). SNI increased Nav1.7 and Nav1.8 cur-
rents, particularly in the slow neuron subpopulation. Because 
the biophysical properties of the different INa components were 
not modified in the slow subpopulation, it is unlikely that the 
increased current density encountered after SNI was due to a 
modification of single-channel properties. The results suggest 
that an increased number of functional channels at the cell 
membrane may be responsible, a mechanism to which NEDD4-
2 downregulation may contribute. This hypothesis is supported 
by the results obtained with the SNS-Nedd4L–/– mice, in which 
an increase in Nav1.7/1.8 current densities was also observed 
in slow neurons and is unlikely due to the modification of sin-
gle-channel properties. The specific roles of fast/slow neuronal 
subpopulations are not yet understood, but the present obser-
vations suggest a role for the slow population in modulating 
thermal sensation.
The protein levels in DRG result from the large intracellular 
pool of Navs and the small Nav fraction at the plasma mem-
brane (36). As a consequence, modifications of Nav expression 
that would be restricted to the plasma membrane may be below 
the sensitivity limits of the assay, thus accounting for the lack 
of observed modification of Nav expression in DRG. Interest-
ingly, both SNI and SNS-Nedd4L–/– mice showed an accumu-
lation of Nav1.7 along the sciatic nerve, suggesting NEDD4-2 
involvement in channel axonal trafficking. The generation of 
SNS-Nedd4L–/– mice enabled us to investigate the functional 
contribution of NEDD4-2 in pain pathways. These mice 
exhibit an abnormal pain phenotype with increased noxious 
heat sensitivity, as revealed in both the hot-plate and plan-
tar tests under basal conditions. Interestingly, the increase in 
thermal hypersensitivity seen with the plantar test in the SNS-
Nedd4L–/– mice reached similar levels to those seen after SNI 
in the injured paws of control littermates. This finding sug-
gests that genetic disruption of NEDD4-2 leads to thermal 
pain hypersensitivity similar to that observed when NEDD4-2 
is pathologically decreased after SNI. Because SNS-Nedd4L–/– 
mice did not develop mechanical allodynia under basal condi-
tions, the decrease in NEDD4-2 is probably not sufficient to 
render these mice mechanically hypersensitive. Neither thermal 
nor mechanical hypersensitivity was enhanced in SNS-Nedd4L–/– 
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mice after SNI, suggesting that a maximum effect of SNI-in-
duced hypersensitivity was reached. This is consistent with the 
fact that NEDD4-2 cannot be further decreased, or only to a 
minor extent, in the DRG of SNS-Nedd4L–/– mice. Finally, the 
responses in the early second phase of the formalin test were 
increased, and the kinetics were accelerated in SNS-Nedd4L–/– 
mice when compared with their controls. This result suggests 
that the peripheral deletion of NEDD4-2 enhances noxious/
nocive inputs in the dorsal horn and that it may be sufficient 
to impact the global mechanisms of central sensitization (37).
The pain behavior of the SNS-Cre mouse line does not differ from 
that of wild-type littermates (38), suggesting that the observed 
hypersensitive phenotype is due to the deletion of NEDD4-2 and 
not to the expression of Cre recombinase in Nav1.8-positive noci-
ceptors. The possibility that these differences may also involve 
non-nociceptive neurons that are potentially subject to Cre recom-
bination cannot be ruled out, as Nav1.8 expression was recently 
shown to extend to larger DRG neurons (39).
Major modifications of Nav1.8 and Nav1.7 density and dis-
tribution were observed in this study. Despite their well-estab-
lished roles in nociception, the mechanisms by which Nav1.7 
and Nav1.8 isoforms specifically contribute to neuropathic 
pain are still under debate. On the one hand, knocking down 
Nav1.8 prevents neuropathic pain in mice (40), Nav1.7 accumu-
lates in human painful dental pulp (15), and gain-of-function 
mutations of Nav1.7 and Nav1.8 are linked to exaggerated pain 
in humans (12, 13). A recent simulation study suggested that 
Nav1.7 and Nav1.8 may act synergistically to increase the ampli-
tude of subthreshold oscillations and increase the frequency of 
repetitive firing in the periphery (41). Increasing their expres-
sion in slow neurons might promote hyperexcitability. How-
ever, in sensory neuron–specific knockouts of Nav1.7, Nav1.8 
or double-knockout mice, neuropathic pain–like behavior still 
develops after nerve injury (18–20). It must be noted that com-
pensatory effects in the expression of the different Nav isoforms 
in genetically modified animals during development cannot be 
excluded. The accumulation of Nav1.7 and Nav1.8 observed 
along the sciatic nerve after SNI has already been reported for 
Nav1.8 in an experimental neuropathic pain model and was 
reported to contribute to neuropathic pain (14).
In the present study, counteracting the SNI-mediated 
decrease in NEDD4-2 using gene transfer further supports the 
functional importance of this ubiquitin ligase in traumatic 
nerve injury–induced neuropathic pain. Gene transfer has 
already been successfully used in mice to alleviate pain (42), 
and clinical trials with vectors engineered to express the pre-
proenkephalin gene for treating cancer pain are underway (43, 
44). In this study, rAAV-mediated overexpression of NEDD4-2 
led to a decrease in Nav1.7 and Nav1.8 current densities in fast 
DRG neurons, which was concomitant with the prevention of 
the full development of mechanical allodynia. It may be that 
rAAV overexpression of NEDD4-2 after nerve injury prevents 
an excess of abnormal peripheral input and reduces activity- 
dependent central sensitization. It is unlikely that the effects 
on mechanical allodynia are due to peripheral changes in the 
activation threshold of low-threshold mechanical afferent 
fibers, since basal mechanical sensitivity was minimally or not 
at all affected by rAAV-NEDD4-2 (nor was it after NEDD4-2 
knockout). The unexpected mechanical hypoalgesic effect of 
rAAV2/6-NEDD4-2 might be due to the ability of ubiquitin 
ligase to regulate other ion channels, such as voltage-gated 
potassium or chloride channels (45), which could inversely 
affect cellular excitability depending on the targeted neuronal 
subpopulation. Despite its effect on the INa of fast DRG neu-
rons, other effects of the viral vector rAAV2/6 on cells or fibers 
in the peripheral nerve cannot be ruled out.
NEDD4-2 was identified as a central in vivo posttranslational 
regulator of Nav1.7 and Nav1.8, whose altered function may con-
tribute to the development of neuropathic pain. Given that the 
abnormal functioning of sodium channels is a key event in the 
etiology of neuropathic pain, these results support a new para-
digm in the treatment of this pathology. Ubiquitylation-depen-
dent mechanisms have already been implicated in neuropathic 
pain in a study reporting that the intrathecal delivery of protea-
some inhibitors attenuated hyperalgesia in rats (46). Another 
posttranslational modification of sodium channels induced by 
the accumulation of the glycolytic metabolite methylglyoxal was 
recently found to play an important role in diabetic neuropathy 
(47). Posttranslational modifications of Nav1.8 accounted for 
small, but significant, changes in the biophysical properties of 
the channel and were responsible for increased excitability of 
primary sensory neurons and sensitivity in diabetic mice. These 
results, together with the findings of this study, strongly sup-
port the need to look for agents that can modulate Nav function 
and that can act as alternatives to the Nav blockers currently 
used to treat neuropathic pain.
The factors that lie upstream of the observed NEDD4-2 decrease 
remain to be identified. Similar to many downregulated genes 
after SNI, axonal injury and the deprivation of trophic factors 
from the target tissue likely influence the transcriptional mecha-
nisms involved in the NEDD4-2 decrease (48).
These results point to NEDD4-2 as a central regulator of noci-
ception and demonstrate that NEDD4-2 dysfunction leads to 
pathological pain. The enhancement of NEDD4-2 activity may 
provide a novel mechanistic alternative to sodium channel block-
ers for the treatment of neuropathic pain. NEDD4-2 may even be 
involved in other neurological diseases linked to altered Nav chan-
nel activity, such as epilepsy and migraine headaches.
Methods
DNA constructs
Human Nedd4L (KIAA0439) cDNA lacking a C2 lipid–binding domain 
cloned into pcDNA3.1 was a gift from T. Nagase (Kazusa DNA Research 
Institute, Kisarazu, Japan). Nav1.7 cDNA cloned into pCIN5h was pro-
vided by S. Tate (Convergence Pharmaceuticals). The QuickChange 
mutagenesis kit (Stratagene) was used to generate Nav1.7 and NEDD4-2 
mutants. Nav1.7 C-terminal PY mutants were generated as follows: 
Pro1944 was mutated into Ala to generate the PA mutant, Tyr1947 into 
Ala to generate the YA mutant, and Val1950 into Ala to generate the VA 
mutant. The NEDD4-2CS mutant was generated by mutating Cys801 
into a Ser. shRNA against NEDD4-2 cloned into a pGIPZ lentiviral vec-
tor was obtained from Open Biosystems. For pull-down experiments, 
the cDNAs encoding the 66 last amino acids of Nav1.7, the 3 different 
PY mutants, and the ubiquitin-binding proteasomal subunit S5A (GST-
S5A) were cloned into pGEX-4T1 (Amersham Bioscience) to generate 
GST fusion proteins.
Western blots, immunofluorescence
See Supplemental Methods.
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Plantar test. The plantar test was conducted by exposing the lateral plan-
tar surface of the paw to a beam of radiant heat through a transparent 
surface. The heat stimulation was repeated 3 times for each paw, and the 
mean latency time was calculated.
Electrophysiology
HEK293 cell recordings. The external and internal solutions used were as 
previously described (ref. 23 and see Supplemental Methods). Data were 
recorded using a VE-2 amplifier (Alembic Instruments) or an Axon 700A 
amplifier and analyzed using pClamp software, version 8 (Molecular 
Devices), KaleidaGraph, version 4.03 (Synergy Software), and MATLAB 
(The MathWorks). The resistance of the borosilicate pipettes (World 
Precision Instruments) was 2–6 MΩ. The leakage current was subtracted 
using the P/4 procedure.
INa densities (pA/pF) were obtained by dividing the peak INa by the cell 
capacitance obtained from the pClamp function. Current densities were 
normalized to WT Nav1.7 or pcDNA3.1 (empty vector control) in the stable 
cell line for each day of the experiment. The Na+ current for the steady-state 
activation (SSA) curves was evoked from a holding potential of −100 mV to 
test pulses of 100 ms ranging from −120 mV to +30 mV in increments of 
5 mV. Steady-state inactivation (SSI) curves were measured from a holding 
potential of −120 mV using 500-ms prepulses to the indicated potentials 
followed by a test pulse to 0 mV. To quantify the voltage dependence of SSA 
and SSI, data from individual cells were fitted with the Boltzmann relation-
ship, y (Vm) = 1 / (1 + exp[(Vm – V1/2) / k]), where y is the normalized current 
or conductance, Vm is the membrane potential, V1/2 is the voltage at which 
half of the available channels are inactivated, and k is the slope factor.
The recovery from inactivation (RFI or “repriming”) curves were 
obtained with a standard 2-pulse protocol consisting of a depolarizing 
pulse from a holding potential of −120 mV to 0 mV for 50 ms to inactivate 
the channels, followed by a variable duration (from 0.5 ms to 3,000 ms) 
step back to −120 mV to promote recovery. The availability of the channels 
was assessed with the first standard test pulse at 0 mV, and the normal-
ized currents of the second pulse at 0 mV were plotted versus the recovery 
interval. We calculated the t1/2 (ms), which is the time necessary for half of 
the channels to recover from the first pulse, by interpolation from a linear 
relation between the 2 points juxtaposing half recovery (y1<0.5<y2), using 
the relation x = [0.5 – (y1x2 – y2x1) / (x2 – x1)] × (x2 – x1) / (y2 – y1).
DRG neuron recordings. Twelve hours after plating, we performed 
whole-cell recordings of small neurons (Cm <30 pF) from L4/5 DRG, 
thought to be nociceptors (27). We used an EPC-10 amplifier and Patch-
master software (both from HEKA Electronics) for data acquisition and 
analysis. The external and internal solutions used were as previously 
described (ref. 49 and see also Supplemental Methods). Pipettes had 
a resistance of less than 3 MΩ, capacity transients were cancelled, and 
series resistance was compensated by approximately 90%. We used data 
only from cells in which the access resistance remained stable through-
out the duration of the experiment. The leakage current was digitally 
subtracted using the P/4 procedure.
INa densities (pA/pF) were obtained by dividing the peak INa by the cell 
capacitance obtained from the HEKA function. Once in whole-cell config-
uration, cells were held at –60 mV for 5 minutes for the following reasons: 
(a) to dialyze the cell with CsF solution; (b) to reach equilibrium of Nav1.8 
(steady-state activation is shifted to hyperpolarized potentials during the 
first few minutes because of CsF); and (c) to lastingly inactivate the Nav1.9 
current (50) in order to prevent contamination of the Nav1.8 current. Cells 
were clamped at –80 mV for 2 more minutes before starting the recordings. 
Activation, SSI, and RFI curves were obtained as described in the in vitro 
experiments, except that each pulse was preceded by a prepulse of 3 sec-
onds at –120 mV to promote recovery of every Navs isoform.
Pull-down and ubiquitylation experiments
pGEX-4T1 containing GST fused to the 66 last amino acids of Nav1.7 WT 
and PY mutants, as well as GST fused to ubiquitin-binding proteasomal 
subunit S5A proteins, were produced (see Supplemental Methods). Pulled-
down proteins were analyzed by Western blot.
Cell-surface biotinylation
HEK293 cells were incubated for 30 minutes at 4°C with biotin solution (0.5 
mg/ml biotin in cold PBS; Pierce Biotechnology) and then rinsed 2 times 
with PBS containing 200 mM glycine followed by 2 rinsings with PBS. Cells 
were then solubilized for 1 hour at 4°C on a wheel, and 50 μl of streptavidin-
neutravidin-sepharose beads (Invitrogen) was incubated in this fraction for 
binding to biotinylated proteins. Samples were analyzed by Western blotting.
Real-time RT-PCR
See Supplemental Methods.
Cell culture and transfection
See Supplemental Methods.
Neuron primary culture
See Supplemental Methods.
Mouse lines
See Supplemental Methods.
Animal surgery
In the SNI experiments, the biceps femoris was incised, exposing the sci-
atic nerve. The tibial and common peroneal nerves were ligated with a silk 
suture (Ethicon) and transected (35).
Viral vector and intrathecal injection
See Supplemental Methods.
Behavioral pain tests
Hot-plate assay. The hot-plate assay was conducted by placing the animals on 
the hot-plate surface set at varying temperatures (49°C, 52°C, and 55°C). 
The latency of response (in seconds) was determined by a hind paw lick or 
jump. The cutoff was adjusted for each temperature to avoid tissue damage 
(60 seconds for 49°C, 30 seconds for 52°C, and 20 seconds for 55°C).
Tail-flick assay. The tail-flick assay was conducted using a tail-flick anal-
gesia meter, and the mice were gently restrained in a conical plastic cloth. 
The latency of response (in seconds) was recorded at 2 different light beam 
intensities (4 and 7 AU).
Pincher test. The pincher test consists of a pair of large blunt forceps 
(15 cm long; flat contact area: 7 mm × 1.5 mm with smooth edges) 
equipped with 2 strain gauges connected to a modified electronic dyna-
mometer (Bioseb). The tips of the forceps were placed around the tail of the 
tested mice, and the force applied was incremented by hand until a with-
drawal response occurred. The measurement was repeated 3 times, and the 
mean force (in grams) that induced withdrawal was calculated.
von Frey assay. The von Frey assay was conducted by applying a series of 
calibrated von Frey filaments on the lateral side of the hind paw’s plantar 
surface (sural nerve territory). Mice were thus placed on a platform with a 
wire netting floor. The mechanical stimulus producing a 50% likelihood of 
withdrawal was determined using the up-down method.
Formalin test. The formalin test was conducted by injecting 10 μl of 5% 
formalin subcutaneously into the left hind paw. The time the animal 
spent shaking or flinching and licking its paw was recorded at 5-minute 
intervals for 60 minutes.
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International Association for the Study of Pain (Zimmermann, 1983). 
Animals were housed under a 12-hour light/12-hour dark cycle and had 
free access to food and water.
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Pharmacological separation of Nav1.7, Nav1.8, and rTTXs sodium currents. 
Navtotal current-voltage (I-V), Navtotal SSI, and Navtotal RFI curves 
were obtained as mentioned above for the total Nav isoform component 
present in DRG neurons. ProTxII (5 nM; provided by B. Priest, Merck 
Serono), a selective blocker of Nav1.7, was then perfused, and a test 
pulse at 0 mM was performed until the diminution of peak amplitude 
reached its steady state (toxin maximal effect). A 5-nM concentration of 
the toxin would block over 90% of Nav1.7 and less than 10% of the other 
isoforms (26). NavtotalProTxII I-V, NavtotalProTxII SSI, and NavtotalProTxII 
RFI were then recorded. Subtracting the total curves for Navtotal I-V, 
Navtotal SSI, and Navtotal RFI from those of NavtotalProTxII I-V, Nav-
totalProTxII SSI, and NavtotalProTxII RFI allowed us to measure Nav1.7 
I-V, Nav1.7 SSI, and Nav1.7 RFI. Finally, TTX (300 mM) was added to 
isolate the Nav1.8 I-V, Nav1.8 SSI, and Nav1.8 RFI curves. Subtracting 
the Nav1.8 I-V, Nav1.8 SSI, and Nav1.8 RFI curves from those of Nav-
totalProTxII I-V, NavtotalProTxII SSI, and NavtotalProTxII RFI allowed us to 
record NavrTTXs I-V, NavrTTXs SSI, and NavrTTXs RFI, representing 
the remainder of the TTX-sensitive current. For examples of this proto-
col for I-V curves, see Figure 3A.
Statistics
For in vitro experiments (current densities, biophysical properties, and 
protein quantification), data were analyzed using an unpaired, 2-tailed 
Student’s t test when 2 groups were compared, or 1-way ANOVA for 
multiple group comparisons. For ex vivo recordings (current densities 
and biophysical properties) and behavioral pain tests, normality was 
tested with a D’Agostino-Pearson omnibus test to determine whether 
parametrical (Student’s t) or nonparametrical (Mann-Whitney U) tests 
would be used when 2 groups were compared. The same normality test 
was performed for multiple group comparisons to determine whether a 
regular 1-way ANOVA and post-hoc Bonferroni’s tests, or the nonpara-
metric equivalence test (Kruskal-Wallis and Dunn’s post tests) would 
be performed. For behavioral pain time courses (von Frey filaments, 
formalin), 2-way ANOVA with repeated measures were performed. The 
statistical tests used are described in each figure legend. A P value less 
than 0.05 was considered significant.
Study approval
All experimental procedures were approved by the Committee on Ani-
mal Experimentation of the Canton de Vaud, Switzerland, in accordance 
with the Swiss Federal Laws on Animal Welfare and the guidelines of the 
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